arrow_back Trending Legislation
Share share

New Opioid Drug Approval Rules: Enhanced Patient Safety.

This bill aims to enhance patient safety by allowing the drug approval agency to reject new opioid drugs if they do not offer a significant advantage over existing ones. This means only drugs that genuinely improve treatment or are safer will reach the market, potentially reducing addiction and overdose risks.
Key points
The drug approval agency can reject new opioid drugs if they are not superior to existing ones.
The goal is to ensure new opioid drugs offer real benefits in terms of safety or effectiveness.
This could limit the availability of opioid drugs that offer no new benefits, potentially reducing misuse risks.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
EFFECTIVE Act
Print number: HR 1375
Sponsor: Rep. Trone, David J. [D-MD-6]
Process start date: 2023-03-03
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about New Opioid Drug Approval Rules: Enhanced Patient Safety.

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 1375.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-03.

What are the main provisions?

Key points include:

  • The drug approval agency can reject new opioid drugs if they are not superior to existing ones.
  • The goal is to ensure new opioid drugs offer real benefits in terms of safety or effectiveness.
  • This could limit the availability of opioid drugs that offer no new benefits, potentially reducing misuse risks.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Trone, David J. [D-MD-6].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

Analysis and Potential Impact of HR 1375

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health